Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation.
Qazilbash MH, Ueno NT, Hosing C, De Lima M, Cortes J, Massaro A, Rivera Z, Deavers M, Adachi JA, Champlin RE. Qazilbash MH, et al. Among authors: ueno nt. Bone Marrow Transplant. 2006 Sep;38(5):393-4. doi: 10.1038/sj.bmt.1705448. Epub 2006 Jul 17. Bone Marrow Transplant. 2006. PMID: 16845427 No abstract available.
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.
Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Körbling M, Giralt S, Gajewski J, Fischer H, Donato M, Cleary K, Claxton D, Chan KW, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R. Przepiorka D, et al. Among authors: ueno nt. Bone Marrow Transplant. 1999 Oct;24(7):763-8. doi: 10.1038/sj.bmt.1701983. Bone Marrow Transplant. 1999. PMID: 10516680
Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1.
Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H, Khouri IF, Folloder J, Ueno NT, Mehra R, Ippoliti C, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Anderlini P, Andersson BS, Champlin R. Przepiorka D, et al. Among authors: ueno nt. Biol Blood Marrow Transplant. 2000;6(2A):190-7. doi: 10.1016/s1083-8791(00)70042-5. Biol Blood Marrow Transplant. 2000. PMID: 10816027 Free article.
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.
Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC Jr, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin RE. Donato ML, et al. Bone Marrow Transplant. 2000 Jun;25(11):1137-40. doi: 10.1038/sj.bmt.1702421. Bone Marrow Transplant. 2000. PMID: 10849525 Clinical Trial.
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Körbling MJ, Manning J, Romaguera J, Sarris A, Rodriguez, Hagemeister F, Mclaughlin P, Cabanillas F, Champlin RE. Anderlini P, et al. Among authors: ueno nt. Bone Marrow Transplant. 2000 Sep;26(6):615-20. doi: 10.1038/sj.bmt.1702580. Bone Marrow Transplant. 2000. PMID: 11041566 Clinical Trial.
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Giralt S, et al. Among authors: ueno nt. Blood. 2001 Feb 1;97(3):631-7. doi: 10.1182/blood.v97.3.631. Blood. 2001. PMID: 11157478 Free article. Clinical Trial.
468 results